GLP-1 drugs in Australia: what the news gets right and wrong

What did @7newsaustralia actually say?

The report claims Australia's government has effectively "robbed" Ozempic users by banning compounded versions of the drug from October, leaving "thousands of patients without a supply." It then quotes former Deputy Chief Health Officer Dr Nick Coatesworth calling for a support package that includes Medicare rebates for exercise programs and dietitians.

This is a news summary, not a medical explainer, so the bar here is accuracy on policy facts rather than clinical depth. The framing is emotionally loaded, but the core facts are checkable. Let's go through them.

Does the science back this up?

The ban on compounded semaglutide is real and the supply concern is legitimate. But the report glosses over why compounded versions exist and why regulators are pulling them.

Compounded semaglutide became widespread in Australia (and the US) during Ozempic and Wegovy shortages. The Therapeutic Goods Administration (TGA) allowed pharmacist-compounded versions under shortage provisions. As brand-name supply has stabilised, those provisions are being wound back. The TGA announced the prohibition on compounded semaglutide products from 1 October 2024, citing concerns about quality, safety and the fact that compounded drugs bypass the standard approval pathway.

The safety concern is not trivial. A 2023 FDA safety communication flagged reports of dosing errors with compounded semaglutide, some resulting in hospitalisations. Compounded products are not bioequivalent to brand-name drugs in any regulatory sense, and quality control varies between compounding pharmacies. The report does not mention any of this context.

Dr Coatesworth's call for allied health support is backed by evidence. Wilding et al. (2021, NEJM) showed that semaglutide's weight loss outcomes were significantly better when combined with lifestyle intervention. Losing that drug without a support bridge is a real clinical problem.

What did they get wrong (or right)?

The report gets the policy timeline roughly right and correctly identifies that patients face a supply gap. That is a genuine public health issue worth reporting on. Credit where it is due.

What it gets wrong, or at least incomplete, is the framing. Calling the ban "robbing" patients implies the government is acting arbitrarily or maliciously. The TGA's rationale, that unregulated compounded products carry safety risks and that brand-name supply has improved, is a defensible regulatory position. Reasonable people can disagree with the decision, but it is not a heist.

The report also says versions "made by pharmacists" will be banned without explaining that compounded drugs are not the same as brand-name semaglutide. They may contain the same active ingredient, but they have not gone through the same manufacturing, stability or bioequivalence testing. Treating them as interchangeable in a news segment risks misleading patients about what they were actually taking.

The "thousands of patients" figure is plausible but unverified in the segment. Estimates from industry groups suggest tens of thousands of Australians were using compounded semaglutide, so "thousands" may actually understate the impact.

What should you actually know?

If you were using compounded semaglutide in Australia, you have a few options worth discussing with a prescriber before October. Brand-name Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management) are both available in Australia through the PBS and private prescription, though access and cost vary.

Dr Coatesworth's point about allied health support is clinically sound. Research consistently shows that stopping a GLP-1 medication without a lifestyle management plan leads to weight regain. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that one year after stopping semaglutide, participants regained two-thirds of the weight they had lost. A Medicare rebate for dietitians and exercise physiologists would be a practical harm-reduction measure, not a luxury.

The broader issue here is that compounded drug markets grow during shortages and regulators then have to unwind them. Patients caught in the middle are not wrong to feel frustrated. But the solution is better access to approved products and genuine clinical support, not indefinite tolerance of unregulated compounding.